Karachi, Otsuka Pakistan Limited informed Pakistan Stock Exchange that Mr. Mikio Bando has been re-appointed as Chairman and Mr. Muhammad Taufiq Feroz and Mr. Sajid Ali have been appointed as Directors of the Board of the Company with effect from November 01, 2021.

Otsuka Pakistan Limited was incorporated in Pakistan as a public limited company and commenced commercial production of Intravenous Solutions in September 1989 at its factory in Hub, Baluchistan.

The Company is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan. Therapeutic Drugs are Otsuka Pakistan’s second line of business; currently consist of Pletaal and Mucosta which are being imported in finished form from Korea.

The total numbers of shares are 12,100,000. The Earnings per share is 7.53 in 2020 which was (14.49) in 2019. The Profit after Taxation is 91,066,000 in 2020 which was 175,348,000 in 2019.